These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22190967)

  • 1. Type 1 diabetes immunological tolerance and immunotherapy.
    Chentoufi AA; Geenen V; Giannokakis N; Amrani A
    Clin Dev Immunol; 2011; 2011():103738. PubMed ID: 22190967
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen-based therapy for the treatment of type 1 diabetes.
    Tian J; Kaufman DL
    Diabetes; 2009 Sep; 58(9):1939-46. PubMed ID: 19720821
    [No Abstract]   [Full Text] [Related]  

  • 3. The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.
    Fraker C; Bayer AL
    Curr Diab Rep; 2016 Nov; 16(11):109. PubMed ID: 27664042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes.
    Muir A; Schatz D; Maclaren N
    Diabetes Metab Rev; 1993 Dec; 9(4):279-87. PubMed ID: 7924825
    [No Abstract]   [Full Text] [Related]  

  • 5. Low-dose IL-2 as a therapeutic agent for tolerance induction.
    Malek TR; Pugliese A
    Immunotherapy; 2011 Nov; 3(11):1281-4. PubMed ID: 22053878
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunotherapy of type 1 diabetes: where are we and where should we be going?
    Luo X; Herold KC; Miller SD
    Immunity; 2010 Apr; 32(4):488-99. PubMed ID: 20412759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Could we cure type 1 diabetes by stimulating T(reg)?].
    Grinberg-Bleyer Y; Baeyens A; Piaggio E; Salomon BL
    Med Sci (Paris); 2011 May; 27(5):471-2. PubMed ID: 21609664
    [No Abstract]   [Full Text] [Related]  

  • 8. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.
    Wang B; Tisch R
    Immunol Res; 2008; 42(1-3):246-58. PubMed ID: 19052699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioengineering strategies for inducing tolerance in autoimmune diabetes.
    Baekkeskov S; Hubbell JA; Phelps EA
    Adv Drug Deliv Rev; 2017 May; 114():256-265. PubMed ID: 28625830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes.
    Nikolic T; Zwaginga JJ; Uitbeijerse BS; Woittiez NJ; de Koning EJ; Aanstoot HJ; Roep BO
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):470-472. PubMed ID: 32723484
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in Type 1 diabetes therapeutics: immunomodulation and beta-cell salvage.
    Waldron-Lynch F; Herold KC
    Endocrinol Metab Clin North Am; 2009 Jun; 38(2):303-17, viii. PubMed ID: 19328413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes.
    Orabona C; Mondanelli G; Puccetti P; Grohmann U
    Trends Mol Med; 2018 Nov; 24(11):931-941. PubMed ID: 30236470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of dendritic cells in the therapy of Type 1 diabetes.
    Lee CN; Lew AM; Wu L
    Immunotherapy; 2013 Jun; 5(6):591-606. PubMed ID: 23725283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of insulin-dependent diabetes mellitus.
    Bach JF
    Curr Opin Immunol; 2001 Oct; 13(5):601-5. PubMed ID: 11544012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational development of antigen-specific therapies for type 1 diabetes.
    Fousteri G; Bresson D; von Herrath M
    Adv Exp Med Biol; 2007; 601():313-9. PubMed ID: 17713020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell mediated therapy for immunoregulation of type 1 diabetes mellitus.
    Phillips BE; Giannoukakis N; Trucco M
    Pediatr Endocrinol Rev; 2008 Jun; 5(4):873-9. PubMed ID: 18552749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunological disorder in diabetes mellitus].
    Takeuchi K; Jodo S; Koike T
    Nihon Rinsho; 1997 Oct; 55 Suppl():700-4. PubMed ID: 9392184
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy in type I diabetes. Approaches to prevention and treatment.
    Colman PG; Eisenbarth GS
    Postgrad Med; 1987 May; 81(6):146-55. PubMed ID: 3554198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 diabetes immunotherapy: is the glass half empty or half full?
    Herold KC; Bluestone JA
    Sci Transl Med; 2011 Aug; 3(95):95fs1. PubMed ID: 21832236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Immunotherapy for Type 1 Diabetes-Clinical Advances.
    Smith EL; Peakman M
    Front Immunol; 2018; 9():392. PubMed ID: 29541078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.